You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Fig. 3

Overall survival (OS) from start of kinase inhibitor therapy. The figures below describe the median OS from the start of kinase inhibitor (KI) therapy. From the start of KI, the median OS was 10.43 months (95% CI = 6.02, 14.83) for the entire cohort (a). On the basis of type of KI (b), median OS was 7.4 months from the start of dabrafenib plus trametinib (95% CI = 0.43, 14.3), 10.4 months from the start of lenvatinib (95% CI = 7.1, 13.8). The patient on trametinib and pembrolizumab (Patient 11) was alive at the time of data analysis 6.7 months from the start of trametinib

Back to article page